Novacyt S.A. (EPA:ALNOV)
France · Delayed Price · Currency is EUR | Market Cap | 34.22M +1.5% |
| Revenue (ttm) | 25.31M +12.0% |
| Net Income | -25.94M |
| EPS | -0.36 |
| Shares Out | 72.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 270,863 |
| Open | 0.4650 |
| Previous Close | 0.4720 |
| Day's Range | 0.4450 - 0.4715 |
| 52-Week Range | 0.2900 - 1.0400 |
| Beta | 1.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 30, 2026 |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the... [Read more]
Financial Performance
In 2025, Novacyt's revenue was 20.03 million, an increase of 2.03% compared to the previous year's 19.63 million. Losses were -22.88 million, -45.20% less than in 2024.
Financial numbers in GBP Financial StatementsNews
Novacyt H1 Loss Narrows As Revenue Rises 18%
(RTTNews) - Novacyt S.A. (NCYT.L), a diagnostics company providing molecular testing technologies and services, reported higher revenue and a narrower loss for the six months ended June 30, 2026.
Novacyt Earnings Call Transcript: H1 2026
Revenue grew to GBP 11.6 million in H1 2026, driven by the Southern Cross acquisition and organic growth. Gross margin declined to 56% due to product mix, but adjusted EBITDA loss improved year-on-year. Restructuring and a new Illumina partnership position the business for future growth.
Novacyt Earnings release: H1 2026
Novacyt released its H1 2026 earnings on September 30, 2026, summarizing the period's financial results.
Novacyt Slides: H1 2026
Novacyt has posted slides in relation to its H1 2026 quarterly earnings report, which was published on September 30, 2026.
Novacyt Quarterly report: H1 2026
Novacyt has published its H1 2026 quarterly earnings report on September 30, 2026.
Novacyt Earnings release: H1 2026
Novacyt released its H1 2026 earnings on July 28, 2026, summarizing the period's financial results.
Novacyt Earnings Call Transcript: H2 2025
Revenue grew 4% year-on-year to GBP 20 million, with strong gross margins and reduced losses. Strategic R&D investment, new product launches, and the Southern Cross acquisition are driving growth, with double-digit revenue growth targeted for 2026.
Novacyt Annual report: H2 2025
Novacyt has published its H2 2025 annual report on April 30, 2026.
Novacyt Annual report: H2 2025
Novacyt has published its H2 2025 annual report on April 30, 2026.
Novacyt Slides: H2 2025
Novacyt has posted slides in relation to its H2 2025 quarterly earnings report, which was published on April 30, 2026.
Novacyt Earnings release: H2 2025
Novacyt released its H2 2025 earnings on April 30, 2026, summarizing the period's financial results.
Novacyt Transcript: Status update
Acquisition of Southern Cross Diagnostics accelerates growth, profitability, and product expansion, with immediate accretive impact and direct access to key customers in Australia and New Zealand. Capital raise was oversubscribed, strengthening the balance sheet and supporting future product launches and partnerships.
Novacyt Earnings release: H2 2025
Novacyt released its H2 2025 earnings on January 21, 2026, summarizing the period's financial results.
Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2022 Results
PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the ...